Abstract Many pharmacological agents are available for the treatment of cardiac arrhythmias. Arrhythmia may be classified on the basis of rate (bradycardia and tachycardia), mechanism (automaticity, re-entry, triggered) or duration (isolated premature beats; couplets). The treatment approach to arrhythmia depends firstly on whether or not the affected person is stable or unstable. This research investigation finds the various pharmacokinetic, bioactivity and toxicity parameters for some selected anti-arrhythmic agents for designing new agents.
Keywords Tachycardia, QSAR, ADMETox, Teratogenicity, MLogP